Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
  • Spinal cord MRI at 7T.

    10 May 2018

    Magnetic resonance imaging (MRI) of the human spinal cord at 7T has been demonstrated by a handful of research sites worldwide, and the spinal cord remains one of the areas in which higher fields and resolution could have high impact. The small diameter of the cord (∼1 cm) necessitates high spatial resolution to minimize partial volume effects between gray and white matter, and so MRI of the cord can greatly benefit from increased signal-to-noise ratio and contrasts at ultra-high field (UHF). Herein we review the current state of UHF spinal cord imaging. Technical challenges to successful UHF spinal cord MRI include radiofrequency (B1) nonuniformities and a general lack of optimized radiofrequency coils, amplified physiological noise, and an absence of methods for robust B0 shimming along the cord to mitigate image distortions and signal losses. Numerous solutions to address these challenges have been and are continuing to be explored, and include novel approaches for signal excitation and acquisition, dynamic shimming and specialized shim coils, and acquisitions with increased coverage or optimal slice angulations.

  • Analysis and correction of field fluctuations in fMRI data using field monitoring.

    14 May 2018

    This work investigates the role of magnetic field fluctuations as a confound in fMRI. In standard fMRI experiments with single-shot EPI acquisition at 3 Tesla the uniform and gradient components of the magnetic field were recorded with NMR field sensors. By principal component analysis it is found that differences of field evolution between the EPI readouts are explainable by few components relating to slow and within-shot field dynamics of hardware and physiological origin. The impact of fluctuating field components is studied by selective data correction and assessment of its influence on image fluctuation and SFNR. Physiological field fluctuations, attributed to breathing, were found to be small relative to those of hardware origin. The dominant confounds were hardware-related and attributable to magnet drift and thermal changes. In raw image time series, field fluctuation caused significant SFNR loss, reflected by a 67% gain upon correction. Large part of this correction can be accomplished by traditional image realignment, which addresses slow and spatially uniform field changes. With realignment, explicit field correction increased the SFNR on the order of 6%. In conclusion, field fluctuations are a relevant confound in fMRI and can be addressed effectively by retrospective data correction. Based on the physics involved it is anticipated that the advantage of full field correction increases with field strength, with non-Cartesian readouts, and upon phase-sensitive BOLD analysis.

  • What are we injecting with our drugs?

    7 December 2017

    In preparation for a case, an anaesthetist opened a 20 ml glass vial of propofol and aspirated the propofol into a syringe via a blunt drawing-up needle. Increased resistance was felt with aspiration. On inspection, a shard of glass was found at the tip of the drawing-up needle. The shard was presumed to be from the propofol ampoule, and to have fallen into the solution upon snapping open its glass tip. This illustrative case raises the issue of contamination of drugs by particles introduced during the drawing-up process. It also highlights the possibility that during the drawing-up process, intravenous drugs may become contaminated not just with particles, but with microorganisms on the surface of the particles. In this article, we discuss relevant recent research of the implications of this type of drug contamination. We draw attention to the need for meticulous care in drawing up and administering intravenous drugs during anaesthesia, particularly propofol.

  • Targeting retinal ganglion cell recovery.

    15 February 2018

    Accumulating evidence from experimental and clinical studies suggest that retinal ganglion cells at least in the earlier stages of glaucoma have the capacity to recover function following periods of functional loss. The capacity for recovery may be negatively impacted by advancing age but can be boosted by interventions such as diet restriction and exercise.

  • A retrospective survey of substance abuse in anaesthetists in Australia and New Zealand from 2004 to 2013.

    26 April 2018

    A questionnaire on substance abuse was distributed electronically to the heads of 185 Australian and New Zealand College of Anaesthetists accredited anaesthesia departments in Australia and New Zealand. The response rate was 57%. From January 2004 to December 2013, 61 cases of substance abuse were identified, giving an estimated incidence of 1.2 cases per 1000 anaesthetist years. Of 44 detailed reports completed, the majority were aged between 30 and 49 years, were male and of specialist grade. However, when corrected for gender and grade, the estimated overall incidence was higher in females and twice as high for trainees compared with specialists. When compared with prior surveys, the pattern of substance abuse in Australia and New Zealand appears to have changed significantly, with a notable increase in propofol and alcohol abuse and a decrease in reported cases of opioid abuse. Common presenting features of abuse included intoxication and witnessed abuse. Seventy percent of cases had more than one comorbid condition, most frequently either mental health or family problems. Only 32% of abusers had made a long-term recovery within the specialty. Death was the eventual outcome in 18% overall, with a particularly high mortality associated with propofol abuse (45%). Trainee suicide from all causes was reported at three times the rate of specialists. The findings indicate that substance abuse remains a significant problem in Australia and New Zealand and is associated with a significant mortality rate.

  • SILENCE

    13 April 2016

    The Sleep in the Intensive Care Unit: Lowering Elements of Noise in the Critical Care Environment (SILENCE) research programme is funded by a feasibility study grant awarded by the NIHR Research for Patient Benefit scheme, and is sponsored by the University of Oxford. Final results are expected late summer 2017.

  • SILENCE

    13 April 2016

  • SILENCE

    13 April 2016

    The SILENCE programme is a series of linked research projects. Updates on progress will be posted here.

  • SILENCE

    13 April 2016

  • SILENCE

    21 April 2017

    Contact details for the SILENCE research programme

  • Non-contact vital signs monitoring

    20 September 2016

    The non-contact vital signs monitoring (NVSM) study is a joint collaboration between the Department of Engineering, the Nuffield Department of Clinical Neurosciences, and Oxehealth Ltd.

  • NVSM

    25 October 2016

    Significant project milestones will be displayed here

  • NVSM

    20 September 2016

    Contact details for the non-contact vital signs monitoring research team

  • NIHR LCRN Studies

    30 June 2016

    The Critical Care Research Group undertakes a number of studies that are adopted by the NIHR local research network portfolio.

  • HAVEN

    10 May 2016

    The HAVEN project is funded by the Health Innovation Challenge Fund, a joint venture supported by the Wellcome Trust and the Department of Health.

  • Oxford Smart Specs Research Group

    13 June 2014

    DCN NLO

    We are developing a set of 'smart' electronic glasses (‘smart specs’) to enhance sight for the visually impaired.

  • Vision Group

    13 February 2014

    FMRIB NLO

    We use brain imaging techniques to investigate the human visual system, both in its normal state and in disease and disorder.

  • FMRIB P.A.I.N Group

    19 January 2015

    FMRIB NDA

    The Pain Analgesia/Anaesthesia Imaging Neuroscience group is a multidisciplinary team of scientists and clinicians. We research how the human central nervous system generates and modulates painful experiences in acute and chronic settings.

  • NeuroMetrology Lab

    13 April 2016

    DCN NDCN

    Our objective is to develop ways of accurately measuring neurological disorders such as Parkinson's disease.

  • Glioma Neurosurgery Research Group

    11 February 2016

    FMRIB NDCN

    Our research aims to understand the characteristics of individual brain tumours, combining cutting edge brain imaging, molecular neuropathology and neurosurgical techniques to develop personalized approaches for first-line cancer surgery.

  • Parkinson’s Neuropathology Group

    23 February 2016

    DCN

    We study why certain neuronal populations are vulnerable to neurodegeneration in Parkinson’s disease brain and whether pathological changes seen in the peripheral tissues mirror or precede what is ultimately seen in the brain, and how this can be used to develop biomarkers.

  • Neuro-Endocrinology Research Group

    11 February 2016

    DCN

    This cross-disciplinary research group links neuropathology, endocrinology and molecular genetics to explore how the genetics and epigenetics of pituitary tumours influences clinical characteristics and to identify targets for therapeutic intervention.

  • Large Artery Disease

    26 August 2016

    CPSD

    CPSD runs several research studies looking into the causes, investigation, and management of large artery atherosclerosis, carotid stenosis, vertebral artery disease and intracranial atherosclerosis.

  • Oxford Vascular Study

    26 August 2016

    CPSD

    The Oxford Vascular Study (OxVasc) investigates vascular diseases (e.g. strokes, heart attacks) in patients registered with eight general practices in Oxfordshire. We run a rapid-access clinic for patients with suspected Transient Ischaemic Attacks (TIAs) or minor strokes.